Funding for this research was provided by:
Department for International Development (300341-102)
Ministerie van Buitenlandse Zaken (PDP15CH14)
Department of Foreign Affairs and Trade, Australian Government (70957)
Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (2020 62 156)
Bill and Melinda Gates Foundation (OPP1113682)
NIH/NIAID (5U19AI109662-05, 5R01AI125197-02, 5U19AI057229)
U.S. Department of Defense (W81XWH-18-1-0253, W81XWH1910235)
Dr. Ralph and Marian Falk Medical Research Trust
Received: 23 March 2021
Accepted: 17 June 2021
First Online: 30 June 2021
: Ethical approvals for the study were obtained respectively from the Phthisiopneumology Institute Chiril Draganiuc (PPI-NRL, Moldova, 7th April 2016, Ref. CE-19.1), the Faculty of Health Sciences UCT Human Research Ethics Committee (UCT, South Africa, 13th February 2014, Ref. 192/2012), and the Ethics Committee of the Universidad Peruana Cayetano Heredia (UPCH, Peru, 11th April 2013, Ref. 4673–4785). The study was undertaken in accordance with the principles of the Helsinki Declaration. Informed written consent was obtained from patients who agreed to participate. Study participation did not affect the standard of care received by the patients.
: Not applicable.
: P.K. is a co-inventor on the 3-gene TB score patent owned by Stanford University (US Patent 10,920,275), which has been licensed for commercialization. P.K. is a consultant with Cepheid. E.S., S.B., L.S.M., J.P., D.G., and D.H.P. are employees of Cepheid.